University of Groningen, Groningen Research Institute of Pharmacy. Interview areas: Pharmaceutical Sciences, Chemistry, Biological Sciences
Wim. J. Quax received his PhD in the field of molecular biology at the University of Nijmegen.
After fulfilling several international research positions he was appointed to full professor in Pharmaceutical Biology at the University of Groningen in 1998. Prof. Quax heads an active research line on using directed evolution and protein design technology for researching pharmaceutically relevant proteins.
Next to his focus on the biosynthesis of natural products, one area of interest are enzymes that interfere with bacterial virulence, which opens new avenues for antibiotics. He has published over 350 peer-reviewed papers and book chapters and he is named inventor on more than 45 patents. He is head of the departments Chemical and Pharmaceutical Biology encompassing 6 professors, 5 post-docs, 4 technicians and 30 PhD students. He has been the supervisor on more than 55 PhD’s with 7 Indonesian students among them.
Since its foundation in 1614, the University of Groningen has enjoyed an international reputation as a dynamic and innovative centre of higher education offering high-quality teaching and research. Balanced study and career paths in a wide variety of disciplines encourage currently more than 32,000 students and researchers to develop their own individual talents. Belonging to the best research universities in Europe and the top 100 universities in the world (see our ranking: https://www.rug.nl/about-ug/profile/facts-and-figures/position-international-rankings, the University of Groningen is truly an international place of knowledge.
Bridging the gap between the fundamental natural sciences (such as chemistry and physics) and the medical/clinical sciences in the field of medicinal products is one of the core activities of the Groningen Research Institute of Pharmacy (GRIP).
GRIP consists of eight research groups and encompasses the entire life span of drugs and diagnostics, from discovery and design, to development and drug use in practice. This approach ensures that our research is of high societal impact, which includes bringing several in-house developed drugs or related products to market, participation in clinical trials, spin-off companies, a strong portfolio of patents and research that contributes directly to healthcare policymaking.